Hims & Hers Just Bought Eucalyptus for $1.15B — What This Mega-Deal Means for TRT Patients in 2026

Hims & Hers Health has announced a landmark $1.15 billion agreement to acquire Eucalyptus, a major Australian digital health platform, in a deal that signals the company's ambitious expansion strategy and could significantly reshape the landscape for testosterone replacement therapy patients. The acquisition, one of the largest in telehealth history, positions Hims & Hers as a truly global player in direct-to-consumer healthcare.

The deal comes at a pivotal moment for Hims & Hers, which recently removed semaglutide products from its platform following FDA enforcement actions against compounded TRT medications. The acquisition of Eucalyptus appears to represent a strategic pivot, expanding the company's service offerings beyond its traditional focus on hair loss, skin care, and sexual health into broader areas of telehealth.

Breaking Down the $1.15 Billion Deal

The acquisition will see Hims & Hers pay $1.15 billion for Eucalyptus, a digital health platform that operates across Australia, the UK, and parts of Europe. Eucalyptus offers virtual healthcare services spanning weight management, mental health, and chronic disease care, making it a complementary addition to Hims & Hers' existing portfolio.

Analysts note that the deal represents a significant premium, reflecting both Eucalyptus's growth trajectory and the strategic value of its platform technology. The acquisition is expected to close in the third quarter of 2026, subject to regulatory approval.

For Hims & Hers, the deal provides immediate scale in international markets while adding capabilities in areas like weight management that go beyond the company's traditional offerings. The combined entity will serve millions of patients across multiple continents.

What This Means for TRT Patients

For patients currently receiving testosterone replacement therapy through Hims & Hers, the acquisition could bring both opportunities and potential changes. The expanded platform may offer more comprehensive services, but patients should also consider how the company's strategic shifts might affect their treatment options.

Recent months have seen Hims & Hers navigate significant regulatory challenges in the TRT space. The company's decision to remove compounded semaglutide products following FDA warnings demonstrated willingness to adapt quickly to changing regulatory landscapes. This same agility may shape how the company approaches TRT going forward.

The acquisition of Eucalyptus may signal increased investment in hormone therapy and related services. Eucalyptus's platform capabilities in chronic disease management could be applied to testosterone therapy, potentially offering patients more comprehensive care coordination.

Telehealth Market Consolidation

This deal represents the latest chapter in the ongoing consolidation of the telehealth industry. As demand for virtual healthcare services continues to grow, companies are seeking scale through acquisition rather than slower organic growth.

The Hims & Hers-Eucalyptus combination creates one of the largest vertically integrated telehealth platforms globally. By bringing together complementary services and geographic reach, the merged entity will be positioned as a dominant player in the direct-to-consumer healthcare market.

For patients, this consolidation could have mixed implications. On one hand, larger platforms may offer more comprehensive services, better technology, and greater investment in care quality. On the other hand, reduced competition could potentially limit choice and potentially affect pricing.

Strategic Context: Post-TRT Pivot

The timing of this acquisition is noteworthy given Hims & Hers' recent challenges in the TRT space. The company was among several telehealth providers to face FDA scrutiny over compounded semaglutide products, ultimately removing these offerings from its platform.

The Eucalyptus acquisition may represent part of a broader strategic repositioning. Rather than competing in the crowded and increasingly regulated TRT market, Hims & Hers appears to be doubling down on other areas where it has established strength, including hormone therapy, hair loss, and mental health.

Eucalyptus brings capabilities in weight management that could be valuable even without semaglutide products. The platform's approach to comprehensive patient care, including coaching, nutrition, and behavioral support, may complement Hims & Hers' existing offerings.

International Expansion

Beyond the strategic service implications, this acquisition represents Hims & Hers' most significant international expansion to date. Eucalyptus operates across Australia, the UK, and parts of Europe, giving Hims & Hers immediate access to these markets.

For American patients, this international expansion may not have immediate practical implications. However, it does signal the company's ambition to build a truly global telehealth platform, which could eventually bring new treatment options and care models to US patients.

The global approach may also bring learnings from different regulatory environments, potentially informing how Hims & Hers navigates the complex US healthcare landscape.

What Patients Should Watch

For current Hims & Hers TRT patients, several factors are worth monitoring in the coming months:

Service integration: The combined platform may offer new features or care coordination tools that could improve the patient experience.

Pricing stability: As the company integrates Eucalyptus and repositions following TRT challenges, pricing for TRT services will be worth watching.

Treatment options: The expanded platform may offer additional treatment modalities or comprehensive care programs.

Regulatory compliance: Hims & Hers has demonstrated willingness to adapt quickly to regulatory changes. Patients should stay informed about any changes to treatment options.

FAQ

Will my TRT treatment through Hims & Hers be affected?

Current indications suggest the acquisition is focused on expanding capabilities rather than restructuring existing services. However, patients should stay informed about any updates to treatment offerings.

Does this acquisition change anything about how I access TRT?

For now, existing patients should continue accessing treatment as normal. The integration process will likely take several months to complete.

Could this acquisition lead to lower TRT prices?

While larger platforms sometimes achieve cost efficiencies, it's too early to predict pricing impacts. The company's recent TRT challenges suggest a focus on sustainable growth rather than aggressive price competition.

Interested in exploring your TRT options? Whether you're considering Hims & Hers or other providers, it's important to find a program that offers quality medical care, competitive pricing, and reliable access to treatment. Compare providers to find the best fit for your needs.